| Pharmacologic agents for mucus clearance in bronchiectasis. | |
| | |
MedLine Citation:
|
PMID: 22640851 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
There are no approved pharmacologic agents to enhance mucus clearance in non-cystic fibrosis (CF) bronchiectasis. Evidence supports the use of hyperosmolar agents in CF, and studies with inhaled mannitol and hypertonic saline are ongoing in bronchiectasis. N-acetylcysteine may act more as an antioxidant than a mucolytic in other lung diseases. Dornase α is beneficial to patients with CF, but is not useful in patients with non-CF bronchiectasis. Mucokinetic agents such as β-agonists have the potential to improve mucociliary clearance in normals and many disease states, but have not been adequately studied in patients with bronchiectasis. |
| | |
Authors:
|
Girish B Nair; Jonathan S Ilowite |
Publication Detail:
|
Type: Journal Article Date: 2012-04-06 |
Journal Detail:
|
Title: Clinics in chest medicine Volume: 33 ISSN: 1557-8216 ISO Abbreviation: Clin. Chest Med. Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-05-29 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7907612 Medline TA: Clin Chest Med Country: United States |
Other Details:
|
Languages: eng Pagination: 363-70 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 Elsevier Inc. All rights reserved. |
Affiliation:
|
Winthrop University Hospital, Mineola, NY, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chest physiotherapy techniques in bronchiectasis.
Next Document: The use of antiinflammatory therapy and macrolides in bronchiectasis.